The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation

Gangabadage, 2008, Structure and dynamics of human apolipoprotein CIII, J. Biol. Chem., 283, 17416, 10.1074/jbc.M800756200 Jong, 1999, Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3, Arterioscler. Thromb. Vasc. Biol., 19, 472, 10.1161/01.ATV.19.3.472 Yao, 2012, Apolipoprotein C–III and hepatic triglyceride-rich lipoprotein production, Curr. Opin. Lipidol., 23, 206, 10.1097/MOL.0b013e328352dc70 Crosby, 2014, Loss-of-function mutations in APOC3, triglycerides, and coronary disease, N. Engl. J. Med., 371, 22, 10.1056/NEJMoa1307095 Jørgensen, 2014, Loss-of-function mutations in APOC3 and risk of ischemic vascular disease, N. Engl. J. Med., 371, 32, 10.1056/NEJMoa1308027 Graham, 2013, Antisense oligonucleotide inhibition of apolipoprotein C–III reduces plasma triglycerides in rodents, nonhuman primates, and humans, Circ. Res., 112, 1479, 10.1161/CIRCRESAHA.111.300367 Ginsberg, 1986, Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo 2, J. Clin. Invest., 78, 1287, 10.1172/JCI112713 Sehayek, 1991, Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway, J. Biol. Chem., 266, 18259, 10.1016/S0021-9258(18)55263-7 Sundaram, 2010, Expression of apolipoprotein C–III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions, J. Lipid Res., 51, 150, 10.1194/jlr.M900346-JLR200 Liu, 2000, Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C–III variant Ala23Thr, J. Lipid Res., 41, 1760, 10.1016/S0022-2275(20)31969-6 von Eckardstein, 1991, Apolipoprotein C–III(Lys58—-Glu). Identi­fication of an apolipoprotein C–III variant in a family with hyperalphalipoproteinemia, J. Clin. Invest., 87, 1724, 10.1172/JCI115190 Sundaram, 2010, Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia, J. Lipid Res., 51, 1524, 10.1194/jlr.M005108 Qin, 2011, J. Biol. Chem., 286, 27769, 10.1074/jbc.M110.203679 Pullinger, 1997, A novel apolipoprotein C–III variant, apoC-III(Gln38→Lys), associated with moderate hypertriglyceridemia in a large kindred of Mexican origin, J. Lipid Res., 38, 1833, 10.1016/S0022-2275(20)37157-1 Vance, 1984, Isolation and analysis of lipoproteins secreted by rat liver hepatocytes, Biochim. Biophys. Acta., 792, 39, 10.1016/0005-2760(84)90280-7 Redgrave, 1979, Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man, J. Lipid Res., 20, 217, 10.1016/S0022-2275(20)40633-9 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods., 25, 402, 10.1006/meth.2001.1262 Hegele, 2015, Targeted next-generation sequencing in monogenic dyslipidemias, Curr. Opin. Lipidol., 26, 103, 10.1097/MOL.0000000000000163 Johansen, 2014, LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias, J. Lipid Res., 55, 765, 10.1194/jlr.D045963 Bradford, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72, 248, 10.1016/0003-2697(76)90527-3 Pollin, 2008, A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection, Science., 322, 1702, 10.1126/science.1161524 Maeda, 1981, Unusual familial lipoprotein C–III associated with apolipoprotein C–III-O preponderance, Biochim. Biophys. Acta., 665, 578, 10.1016/0005-2760(81)90273-3 Maeda, 1987, Molecular cloning of a human apoC-III variant: Thr 74—-Ala 74 mutation prevents O-glycosylation, J. Lipid Res., 28, 1405, 10.1016/S0022-2275(20)38574-6 Lüttmann, 1994, Electrophoretic screening for genetic variation in apolipoprotein C–III: identification of a novel apoC-III variant, apoC-III(Asp45→Asn), in a Turkish patient, J. Lipid Res., 35, 1431, 10.1016/S0022-2275(20)40084-7 Valleix, 2016, D25V apolipoprotein C–III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile, Nat. Commun., 7, 10353, 10.1038/ncomms10353 Segrest, 1990, Amphipathic helix motif: classes and properties, Proteins., 8, 103, 10.1002/prot.340080202 Liu, 2000, Characterization of recombinant wild type and site-directed mutations of apolipoprotein C–III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase, Biochemistry., 39, 9201, 10.1021/bi0009441 Lee, 2011, Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance, Hepatology., 54, 1650, 10.1002/hep.24571 Salerno, 2007, Overexpression of apolipoprotein CIII increases and CETP reverses diet-induced obesity in transgenic mice, Int. J. Obes.(Lond)., 31, 1586, 10.1038/sj.ijo.0803646 Takahashi, 2003, Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice, Metabolism., 52, 1354, 10.1016/S0026-0495(03)00202-6 Duivenvoorden, 2005, Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice, Diabetes., 54, 664, 10.2337/diabetes.54.3.664 Duran-Sandoval, 2004, Glucose regulates the expression of the farnesoid X receptor in liver, Diabetes., 53, 890, 10.2337/diabetes.53.4.890 Caron, 2011, Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia, Arterioscler. Thromb. Vasc. Biol., 31, 513, 10.1161/ATVBAHA.110.220723